GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acrux Ltd (OTCPK:ARUXF) » Definitions » Other Operating Expense

Acrux (ARUXF) Other Operating Expense : $1.15 Mil (TTM As of Dec. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Acrux Other Operating Expense?

Acrux's Other Operating Expense for the six months ended in Dec. 2024 was $0.59 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 was $1.15 Mil.

Acrux's quarterly Other Operating Expense increased from Dec. 2023 ($0.45 Mil) to Jun. 2024 ($0.56 Mil) and increased from Jun. 2024 ($0.56 Mil) to Dec. 2024 ($0.59 Mil).

Acrux's annual Other Operating Expense declined from Jun. 2022 ($1.70 Mil) to Jun. 2023 ($1.26 Mil) and declined from Jun. 2023 ($1.26 Mil) to Jun. 2024 ($1.01 Mil).

Acrux Other Operating Expense Historical Data

The historical data trend for Acrux's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acrux Other Operating Expense Chart

Acrux Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.64 1.76 1.70 1.26 1.01

Acrux Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.58 0.68 0.45 0.56 0.59

Acrux Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $1.15 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acrux Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Acrux's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Acrux Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acrux Ltd (OTCPK:ARUXF) » Definitions » Other Operating Expense
Comparable Companies
ASX:MEM ASX:1AI ASX:CHM ASX:NSB ASX:PAB ASX:AVE ASX:TRP ASX:CMB ASX:IXC ASX:BGT VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
FJY:Germany ACR:Australia
Address
103-113 Stanley Street, West Melbourne, Melbourne, VIC, AUS, 3003
Website
https://www.acrux.com.au
Acrux Ltd is a pharmaceutical company dedicated to developing and commercializing generic transdermal and topical prescription pharmaceuticals. The group is formulating and developing a range of topical generic products by leveraging its skilled workforce, on-site laboratories, GMP manufacturing suite, and technical, clinical, and commercial experience to bring affordable products to market. Geographically, it has a presence in Australia; the United States; Europe, and other countries. The firm operates in a single segment and derives revenue from developing and commercializing pharmaceutical products that administer drugs topically. Its product pipeline products include Lenzetto, Evamist, Testosterone Topical Solution, and among others.